Dylan Deng from San Diego, CA

view source

Location:

San Diego, CA

Industry:

Biotechnology

Work:

Concortis Biosystems
Sen Scientist

Anti-Erbb2 Antibody-Drug Conjugate And Composition Thereof, Preparation Method Therefor, And Application Thereof
view source
US Patent:

20190076438, Mar 14, 2019
Filed:

Nov 22, 2016
Appl. No.:

15/765685
Inventors:

- Chengdu, Sichuan, CN
Zhenwei MIAO - San Diego CA, US
Jing WANG - Chengdu, Sichuan, CN
Gang CHEN - San Diego CA, US
Yan QING - Chengdu, Sichuan, CN
Tong ZHU - San Diego CA, US
Liang XIAO - Chengdu, Sichuan, CN
Hong ZHANG - San Diego CA, US
Qiuyan YANG - Chengdu, Sichuan, CN
Dylan Dalun DENG - San Diego CA, US
Liping LIU - Chengdu, Sichuan, CN
Hong ZENG - Chengdu, Sichuan, CN
Li YIN - Chengdu, Sichuan, CN
Qifeng SHI - Chengdu, Sichuan, CN
Hongmei SONG - Chengdu, Sichuan, CN
Xi ZHAO - Chengdu, Sichuan, CN
Lichun WANG - Chengdu, Sichuan, CN
Jingyi WANG - Chengdu, Sichuan, CN
Assignee:

SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. - Chengdu, Sichuan
International Classification:

A61K 31/536
A61P 35/00
C07K 16/32
A61K 47/64
A61K 47/65
A61K 47/68
Abstract:

The present invention provides an anti-ErbB2 antibody-drug conjugate, a composition comprising the conjugate, a method for preparing the conjugate, use of the conjugate.

Antibody Drug Conjugates
view source
US Patent:

20170224835, Aug 10, 2017
Filed:

Feb 5, 2016
Appl. No.:

15/017174
Inventors:

- San Diego CA, US
Gang Chen - San Diego CA, US
Tong Zhu - San Diego CA, US
Alisher B. Khasanov - San Diego CA, US
Dylan Deng - San Diego CA, US
Hong Zhang - San Diego CA, US
Zheng Yan - San Diego CA, US
Assignee:

Sorrento Therapeutics, Inc. - San Diego CA
International Classification:

A61K 47/48
A61K 31/65
Abstract:

There is disclosed antibody drug conjugates having anthracycline derivative drug moieties that provide improved safety and cell killing efficacy, wherein the anthracycline derivative drug moieties substitute an hydroxymethyl ketone moiety for an hydrazide or hydroxamate moiety. The disclosed cytotoxic agents (i.e., drug moieties) are conjugated to an antibody via either a Cys or a Lys residue. For Lys conjugation, the DAR (drug antibody ratio) of the majority of the ADC is 2 whereas the DAR of the majority of ADC is 4 when conjugation occurs on a Cys residue.

Antibody Drug Conjugates
view source
US Patent:

20170190736, Jul 6, 2017
Filed:

Jan 28, 2016
Appl. No.:

15/009775
Inventors:

- San Diego CA, US
Gang Chen - San Diego CA, US
Tong Zhu - San Diego CA, US
Alisher B. Khasanov - San Diego CA, US
Dylan Deng - San Diego CA, US
Hong Zhang - San Diego CA, US
Assignee:

Sorrento Therapeutics, Inc. - San Diego CA
International Classification:

C07K 5/062
C07K 16/32
Abstract:

There is disclosed a Dolastatin derivative, conjugated to an antibody, comprising a Dolastatin derivative moiety of Formula IV.

Dylan Deng